These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31167968)

  • 1. Ryanodine receptor-bound calmodulin is essential to protect against catecholaminergic polymorphic ventricular tachycardia.
    Nakamura Y; Yamamoto T; Kobayashi S; Tamitani M; Hamada Y; Fukui G; Xu X; Nishimura S; Kato T; Uchinoumi H; Oda T; Okuda S; Yano M
    JCI Insight; 2019 Jun; 4(11):. PubMed ID: 31167968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defective calmodulin binding to the cardiac ryanodine receptor plays a key role in CPVT-associated channel dysfunction.
    Xu X; Yano M; Uchinoumi H; Hino A; Suetomi T; Ono M; Tateishi H; Oda T; Okuda S; Doi M; Kobayashi S; Yamamoto T; Ikeda Y; Ikemoto N; Matsuzaki M
    Biochem Biophys Res Commun; 2010 Apr; 394(3):660-6. PubMed ID: 20226167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor.
    Uchinoumi H; Yano M; Suetomi T; Ono M; Xu X; Tateishi H; Oda T; Okuda S; Doi M; Kobayashi S; Yamamoto T; Ikeda Y; Ohkusa T; Ikemoto N; Matsuzaki M
    Circ Res; 2010 Apr; 106(8):1413-24. PubMed ID: 20224043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation-linked, excessively tight interaction between the calmodulin binding domain and the C-terminal domain of the cardiac ryanodine receptor as a novel cause of catecholaminergic polymorphic ventricular tachycardia.
    Nishimura S; Yamamoto T; Nakamura Y; Kohno M; Hamada Y; Sufu Y; Fukui G; Nanno T; Ishiguchi H; Kato T; Xu X; Ono M; Oda T; Okuda S; Kobayashi S; Yano M
    Heart Rhythm; 2018 Jun; 15(6):905-914. PubMed ID: 29427818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia.
    Shan J; Xie W; Betzenhauser M; Reiken S; Chen BX; Wronska A; Marks AR
    Circ Res; 2012 Aug; 111(6):708-17. PubMed ID: 22828895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced binding of calmodulin to RyR2 corrects arrhythmogenic channel disorder in CPVT-associated myocytes.
    Fukuda M; Yamamoto T; Nishimura S; Kato T; Murakami W; Hino A; Ono M; Tateishi H; Oda T; Okuda S; Kobayashi S; Koseki N; Kyushiki H; Yano M
    Biochem Biophys Res Commun; 2014 May; 448(1):1-7. PubMed ID: 24755079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Divergent regulation of ryanodine receptor 2 calcium release channels by arrhythmogenic human calmodulin missense mutants.
    Hwang HS; Nitu FR; Yang Y; Walweel K; Pereira L; Johnson CN; Faggioni M; Chazin WJ; Laver D; George AL; Cornea RL; Bers DM; Knollmann BC
    Circ Res; 2014 Mar; 114(7):1114-24. PubMed ID: 24563457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2.
    Klipp RC; Li N; Wang Q; Word TA; Sibrian-Vazquez M; Strongin RM; Wehrens XHT; Abramson JJ
    Heart Rhythm; 2018 Apr; 15(4):578-586. PubMed ID: 29248564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Calmodulin Variant p.E46K Associated With Severe Catecholaminergic Polymorphic Ventricular Tachycardia Produces Robust Arrhythmogenicity in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Gao J; Makiyama T; Yamamoto Y; Kobayashi T; Aoki H; Maurissen TL; Wuriyanghai Y; Kashiwa A; Imamura T; Aizawa T; Huang H; Kohjitani H; Nishikawa M; Chonabayashi K; Fukuyama M; Manabe H; Nakau K; Wada T; Kato K; Toyoda F; Yoshida Y; Makita N; Woltjen K; Ohno S; Kurebayashi N; Murayama T; Sakurai T; Horie M; Kimura T
    Circ Arrhythm Electrophysiol; 2023 Mar; 16(3):e011387. PubMed ID: 36866681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Liu B; Walton SD; Ho HT; Belevych AE; Tikunova SB; Bonilla I; Shettigar V; Knollmann BC; Priori SG; Volpe P; Radwański PB; Davis JP; Györke S
    J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29720499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation-linked defective interdomain interactions within ryanodine receptor cause aberrant Ca²⁺release leading to catecholaminergic polymorphic ventricular tachycardia.
    Suetomi T; Yano M; Uchinoumi H; Fukuda M; Hino A; Ono M; Xu X; Tateishi H; Okuda S; Doi M; Kobayashi S; Ikeda Y; Yamamoto T; Ikemoto N; Matsuzaki M
    Circulation; 2011 Aug; 124(6):682-94. PubMed ID: 21768539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational Analysis of Binding Interactions between the Ryanodine Receptor Type 2 and Calmodulin.
    Greene D; Barton M; Luchko T; Shiferaw Y
    J Phys Chem B; 2021 Sep; 125(38):10720-10735. PubMed ID: 34533024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2(R2474S/+) knock-in mouse model.
    Kobayashi S; Yano M; Uchinoumi H; Suetomi T; Susa T; Ono M; Xu X; Tateishi H; Oda T; Okuda S; Doi M; Yamamoto T; Matsuzaki M
    Circ J; 2010 Nov; 74(12):2579-84. PubMed ID: 20944434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac myocyte Z-line calmodulin is mainly RyR2-bound, and reduction is arrhythmogenic and occurs in heart failure.
    Yang Y; Guo T; Oda T; Chakraborty A; Chen L; Uchinoumi H; Knowlton AA; Fruen BR; Cornea RL; Meissner G; Bers DM
    Circ Res; 2014 Jan; 114(2):295-306. PubMed ID: 24186966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The arrhythmogenic N53I variant subtly changes the structure and dynamics in the calmodulin N-terminal domain, altering its interaction with the cardiac ryanodine receptor.
    Holt C; Hamborg L; Lau K; Brohus M; Sørensen AB; Larsen KT; Sommer C; Van Petegem F; Overgaard MT; Wimmer R
    J Biol Chem; 2020 May; 295(22):7620-7634. PubMed ID: 32317284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arrhythmogenic Calmodulin Mutations Affect the Activation and Termination of Cardiac Ryanodine Receptor-mediated Ca2+ Release.
    Søndergaard MT; Tian X; Liu Y; Wang R; Chazin WJ; Chen SR; Overgaard MT
    J Biol Chem; 2015 Oct; 290(43):26151-62. PubMed ID: 26309258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model.
    Liu N; Colombi B; Memmi M; Zissimopoulos S; Rizzi N; Negri S; Imbriani M; Napolitano C; Lai FA; Priori SG
    Circ Res; 2006 Aug; 99(3):292-8. PubMed ID: 16825580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity of ryanodine receptor dysfunction in a mouse model of catecholaminergic polymorphic ventricular tachycardia.
    Loaiza R; Benkusky NA; Powers PP; Hacker T; Noujaim S; Ackerman MJ; Jalife J; Valdivia HH
    Circ Res; 2013 Jan; 112(2):298-308. PubMed ID: 23152493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CaMKII-dependent phosphorylation of RyR2 promotes targetable pathological RyR2 conformational shift.
    Uchinoumi H; Yang Y; Oda T; Li N; Alsina KM; Puglisi JL; Chen-Izu Y; Cornea RL; Wehrens XHT; Bers DM
    J Mol Cell Cardiol; 2016 Sep; 98():62-72. PubMed ID: 27318036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenic mechanism of a catecholaminergic polymorphic ventricular tachycardia causing-mutation in cardiac calcium release channel RyR2.
    Xiong J; Liu X; Gong Y; Zhang P; Qiang S; Zhao Q; Guo R; Qian Y; Wang L; Zhu L; Wang R; Hao Z; Wen H; Zhang J; Tang K; Zang WF; Yuchi Z; Chen H; Chen SRW; Zheng W; Wang SQ; Xu YW; Liu Z
    J Mol Cell Cardiol; 2018 Apr; 117():26-35. PubMed ID: 29477366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.